**Dupixent – Prix Galien 2021**

**SECTION 4: DEVELOPMENT (300 words max)**

**Current Word Count: 266**

In 2007, Regeneron and Sanofi entered into a global collaboration for the development and commercialization of dupilumab in type 2 inflammatory diseases. To date, dupilumab has been studied in more than 10,000 patients across 50 clinical trials in various chronic diseases driven by type 2 inflammation, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP), with additional studies in eosinophilic esophagitis, chronic obstructive pulmonary disease with evidence of type 2 inflammation, bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria, chronic inducible urticaria-cold, chronic rhinosinusitis without nasal polyposis, allergic fungal rhinosinusitis, allergic bronchopulmonary aspergillosis and food allergies. Dupilumab has demonstrated unprecedented clinical efficacy in four allergic diseases to date, with many more studies underway or planned. Dupixent (dupilumab) has already revolutionized the treatment of atopic dermatitis by improving thousands of patients’ lives, including the most recent expansion of the indication to include children as young as 6 years old. It is also emerging as the treatment of choice for uncontrolled moderate-to-severe asthma and CRSwNP.

Dupilumab has given new hope for previously untreatable eosinophilic esophagitis, based on positive data from part A of a Phase 3 trial.5 Dupilumab is the first and only biologic to show positive and clinically-meaningful results in patients with have difficulty swallowing food due to type 2 inflammation in their esophagus.5 Dupilumab demonstrated significant clinical and anatomic improvements, including 69% improvement in the ability to swallow. Part B of the Phase 3 trial is ongoing.5

Dupilumab treatment has resulted in unprecedented efficacy in every type 2 inflammatory condition in which results have been available.

*References*

1. Dupixent Prescribing Information. June 2020.

2. Gandhi NA, BL Bennett, NM Graham, et al. Targeting key proximal drivers of type 2 inflammation in disease. *Nat Rev Drug Discov.* 2016;15(1):35-50.

3. Data on file.

4. Dupixent (dupilumab). U.S. Prescribing Information. 2020.

5. “DUPIXENT® (DUPILUMAB) EOSINOPHILIC ESOPHAGITIS TRIAL MEETS BOTH CO-PRIMARY ENDPOINTS.” 22 May 2020. Press Release. Accessed at: <https://newsroom.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-eosinophilic-esophagitis-trial-meets-both-co>

6. Snapper CM, Finkelman FD, Paul WE. Regulation of IgG1 and IgE production by interleukin 4. Immunological reviews. 1988 Apr 1;102(1):51-75.

7. Aversa G, Punnonen J, Cocks BG, de Waal Malefyt R, Vega F, Zurawski SM, Zurawski G, De Vries JE. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors. Journal of Experimental Medicine. 1993 Dec 1;178(6):2213-8.

8. Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. *Proc Natl Acad Sci USA.* 2014;111(14):5147-52.